NTRINSIC OR ACQUIRED resistance to antineoplastics limits the effectiveness of conventional treatment in acute myeloid leukemia (AML).
Multidrug resistance (MDR) resulting from overexpression of the MDRl gene or its plasma membrane product, P-glycoprotein (Pgp), has been implicated as a cellular mechanism contributing to chemotherapy resistance in this disease.' Pgp has been linked to a number of adverse prognostic variables including age, leukemia arising secondary to an antecedent hematologic disorder or cytotoxic therapy, cytogenetic pattern, and a CD34 surface phenotype."' Leukemias expressing the MDRl phenotype show lower intracellular drug accumulation'.' and diminished in vitro and in vivo sensitivity to the anthra~yclines.~.~.' For this reason, agents capable of reversing Pgp-mediated drug resistance in vitro have entered clinical testing as modulators of MDR."'."
The predictive value of Pgp as an independent marker for
I
From treatment failure has been questioned in some studies.*," The reported incidence of MDRl overexpression in clinically resistant leukemia shows considerable variation, and its correlation with in vitro chemosensitivity has been inconsistent,13-16
In a phase 1/11 trial evaluating cyclosporin-A as a modulator of MDR, we found that in remitting patients MDRl gene message decreased or was absent at the time of relapse, thereby implicating alternate mechanisms of chemotherapy resistance."
Recent evidence indicates that mechanisms other than Pgp contribute to the MDR phenotype in human malignan~ies.""~ The MDR-associated protein (MRP) is a member of the adenosine triphosphate-binding cassette ( B C ) superfiunily of membrane transporters that confers resistance to anthracyclines and other natural products in tumor cell lines.l*.*" Investigations of the prognostic relevance of MRP in AML remain inconclusive, showing infrequent overexpression in poor-risk cohorts but relative increase in gene message after treatment failure.2'." The monoclonal antibody (MoAb) LW56 recognizes a l IO-M) protein initially identified in the Pm-, MDR lung cancer cell line SW 1573/2R120 and termed lung-resistance protein (LRP).'y.27 Overexpression of LRP is demonstrable in tumor cell lines of diverse histiogenic origin that lack Pgp or MRP overexpression, but that show an energy-dependent drug accumulation defect weakly sensitive to chemosensitizers such as verapamil and cycl~sporin-A.'".'~ Immunocytochemical staining with LRP56 is principally cytoplasmic in a coarsely granular pattern, indicating reactivity with a molecule closely associated with endomembrane structures. Recent investigations indicate that L W is a highly conserved major vault protein implicated in nuclear-cytoplasmic tran~port.~'.~ To determine the clinical relevance of this novel drug-resistance phenotype, we evaluated the frequency of antibody staining and the prognostic significance of L W overexpression in clinical specimens from patient5 with AML. ; n = 24). Remaining patients with relapsed or secondary AML received either high-dose cytarabine (HiDAC; 3 g/mz/day for 5 days) followed by DNR and cyclosporin-A (Sandimmune; Sandoz, East Hanover, NJ) as previously described" (n = 34), HiDAC plus DNR or mitoxantrone without cyclosporine (n = 6). or mitoxantrone (IO mg/m2/d for 5 days) and etoposide (100 mg/m2/d for 5 days; n = 3). Eleven patients were not evaluable for response, including 5 elderly patients with secondary AML who refused induction therapy and 6 patients who underwent bone marrow (BM) transplantation.
MATERIALS AND METHODS

Patients
Response assessment. Response to treatment was assessed after a maximum of two courses of conventional-dose induction chemotherapy or after one course of an HiDAC-containing regimen. A partial response required normal peripheral blood counts with a BM aspirate containing greater than 5% but less than 25% blasts or a BM aspirate with less than 5% blasts in the presence of moderate thrombocytopenia (50,000 to lOO,OOO/pL platelets) in a patient with secondary AML.
Cytogenetics. Cytogenetic analysis was performed on BM aspirates from patients with previously untreated AML by routine Giemsa-banding techniques after 24-hour culture and methotrexate synchronization, as previously described.*' Chromosome abnormaiities were analyzed separately for relationship to LRP56 staining and according to prognostic groups using a modification of the Chicago classification in which t(8;21), abnormal 16, and t(15; 17) were considered favorable and a normal karyotype of intermediate prognosis, whereas numerical or structural deletions of chromosomes 5 or 7, trisomy 8, complex patterns, and other chromosome abnormalities were considered unfavorable.** Immunocytochemistry. Mononuclear cell fractions were isolated from heparinized BM aspirates by double Ficoll-Hypaque density gradient centrifugation. Cytospins were prepared, and the blast reactivity with the MoAb LRP56 (Dr R.J. Scheper, Free University Hospital, Amsterdam, the Netherlands) and the Pgp-specific antibodies JSB-I (Sanbio bv, Uden, the Netherlands) and MRK16 (a gift of Dr T. Tsuruo, University of Tokyo, Tokyo, Japan) were determined by indirect immunoperoxidase using a previously described modified biotin-avidin technique.19.z9 Sensitive parental (8226/s) and two MDR human myeloma cell lines selected with either mitoxantrone for non-Pgp MDR (MR20) or doxorubicin for classical MDR (Dox6) served as negative, LRP56+, or Pgp+ controls, respectively. Immunostained slides were scored without knowledge of clinical outcome, and specimens with reactivity in 220% of the blast fraction were considered positive.
Cytoj%orogruphy. Surface-marker analysis was performed by flow cytometry using MoAbs directed against Pgp (MRK16), CD34 (Becton Dickinson, Mountain View, CA), CD7 (Becton Dickinson), and myeloid-specific antigens." Cell suspensions were incubated with MoAbs for 30 , and all twoway interaction terms on both overall and progression-free survival.
RESULTS
Immunocytochemical staining with LW56 was localized to the cytoplasm in a granular pattern as shown in Fig 1. The results of immunocytochemical staining for LRP and Pgp in 87 patient specimens is summarized in Table 1 . Thirty-two specimens showed immunoreactivity in 20% or more of the blast population. LRP overexpression was detected in all disease categories, ranging in frequency from 10% in patients with CML-BP to 48% in patients with secondary AML. Among 66 patients with AML evaluable for response to induction chemotherapy, 36 achieved a complete (n = 32) or partial (n = 4) remission. LRP overexpression was associated with response to induction therapy ( P = .0036); 68% of LW-patients achieved a hematologic remission as compared with 35% of LRP' patients ( Table 2) . This difference in response resulted from a corresponding higher prevalence of resistant disease in the LW+ cohort. Both Pgp and LRP overexpression had an adverse impact on response to induction therapy in univariate analyses ( P = .M14 and P = .0017, respectively). When analyzed according to both LRP and Pgp staining pattern, LRP retained prognostic significance (P = .0046), whereas Pgp did not (P = .147). A similar effect was observed after adjusting for disease category (ie, de novo, secondary, or relapsed), with only LRP retaining prognostic significance (P = .0035 v P = .l13 for L W and Pgp, respectively). Although patients with both L W and Pgp overexpression had the lowest remission rate (31%) and the highest prevalence of resistant disease (56%; see Table 3 ), a significant interaction between LRP and Pgp was not shown in the logistic regression model ( P = .358).
The probability of remaining in complete remission and of overall survival were analyzed according to LRP and Pgp phenotype. Median remission duration was 1 month in LW' patients and 4 months in the LW-cohort. Neither LRP ( P = .0752) nor Pgp ( P = .0646) significantly affected remission duration for the group as a whole. However, within defined disease categories, LRP had an adverse impact on progression-free survival for patients with secondary AML in logrank analysis ( P = .0361). approached significance for LRP ( P = .058) but not for Pgp ( P = .093; see Fig 2) .
Differences in overall survival
Characteristics of treatment that might select for the LRP phenotype were analyzed in the relapsed patient cohort. Prior treatment with mitoxantrone was associated with a significantly higher probability of LRP56 reactivity (64%) as compared with that for patients receiving DNR or idarubicin (18%; P = .020). Sequential samples from 17 patients obtained before treatment with DNR and cyclosporin-A and at the time of disease progression were available for analysis (Table 4) . Those patients experiencing an initial response to induction therapy showed acquisition of LRP at the time of relapse ( P = .0304), despite a loss or a decrease in frequency of Pgp expression. A significant change in LRP expression in patients resistant to cyclosporine-modulation was not observed ( P = .32).
Among clinical and biological prognostic variables analyzed for relationship to LRP, significant correlations were found with Pgp ( P = .040) and age greater than 55 years ( P = ,017). No association was found with CD34, CD7, or specific chromosome abnormalities. Cytogenetic analysis was successful in 47 of the 48 patients with de novo or secondary AML, and 23 patients had an abnormal karyotype ( Table 5 ). There was no difference in the prevalence of LRP overexpression among patients with a normal versus abnormal karyotype ( P = 3 6 ) . Although LRP overexpression was detected in only 1 of 8 cases (12%) with a favorable cytogenetic abnormality as compared with 7 of 15 cases (47%) with an unfavorable karyotype, this difference was not statistically significant ( P = .176).
DISCUSSION
Clinical resistance to chemotherapy results from the interaction of numerous biological variables. In this study, we found that overexpression of the novel major vault transporter protein, LRP, has prognostic significance in AML. The gene encoding LRP was recently cloned and localized to chromosome 16~11.2 proximal to the MRP gene.26 Although LRP bears no significant homology to the adenosine triphosphate-binding cassette (ABC) membrane transporter superfamily, it shows striking identity to the major vault protein (mVp), mVp-a. Vaults are highly conserved ribonucleoprotein complexes localized to nuclear membrane pores and cytoplasmic vesicles and are implicated in nuclear-cytoplasmic tran~port.'~.'~ Fluorescence microscopy studies support a similar function for LRP, showing rapid anthracycline redistribution from the nucleus to cytoplasmic vesicles in cell lines overexpressing the pr~tein.'~.'~ Given that vaults In the present study, LRP overexpression was detected in 37% of patient specimens, including both previously treated and untreated patients (Table 1 ). Similar to that for Pgp, the highest frequency of detection was found in secondary AML (48%). However, LRP overexpression was uncommon in CML-BP (lo%), indicating that other mechanisms, including Pgp, may contribute to chemotherapy resistance in this disease. Although the frequency of LRP detection in the relapsed patient cohort was identical to that for Pgp (38%), only prior treatment with mitoxantrone was associated with LRP overexpression. This finding is consistent with results of in vitro drug selection studies, indicating that mitoxantrone, rather than the anthracyclines, preferentially selects for the LRP Despite treatment and cohort heterogeneity, L W was an important predictor of response to induction chemotherapy in patients with AML, independent of disease category. After adjusting for potential differences related to diagnostic group, LRP+ patients had a significantly lower remission rate and higher probability of resistant failure than did LRP-patients ( P = .0035). Because Pgp expression was common in LRP' specimens, stratification of outcome according to drug-resistance phenotype was analyzed to discern the relative contribution of each drugresistance marker. As shown in Table 3 , LRP overexpression was shown in the absence of Pgp, and each marker adversely influenced response to induction therapy. However, when adjusted for Pgp, only LRP retained prognostic significance ( P = .0046). Although the prognostic impact of each marker appeared additive, a significant interaction was not shown in a logistic regression model. It is possible that the prognostic effect of Pgp was obscured by treatment with the Pgp modulator cyclosporin-A in some patients. If so, pretreatment screening of patient specimens for each of these drug-resistance markers may identify patients at greatest risk for treatment failure with conventional therapy, who might, therefore, be considered for alternate treatment strategies.
Previous investigations have shown that Pgp overexpression is principally restricted to CD34+ blast populations, a pattern that mirrors its regulation in normal hemat o p o i e s i~.~"~~~~~' Although we found no correlation between LRP and CD34, there was a trend favoring association with CD7. LRP overexpression was detected in 63% of CD7' specimens as compared with 34% of specimens lacking a CD7 surface phenotype ( P = .122). In view of recent reports that CD7 may have prognostic relevance in AML, LRP may contribute to the adverse biological behavior observed in this phenotypic This observation warrants further study in a larger group of patients.
LRP was associated with adverse prognostic variables including advanced age and Pgp, but no correlation was found with specific chromosome abnormalities ( Table 5 ).
The latter finding may relate to the comparatively small number of previously untreated patients analyzed. However, among karyotypically abnormal patients, LRP was detected in only 1 of 8 specimens harboring a favorable cytogenetic abnormality, as compared with 47% of cases with an unfavorable karyotype. We and others have reported a similar relationship between Pgp and cytogenetic indicating that leukemias harboring such favorable karyotypic abnormalities may have a more limited cytoprotective repertoire. Treatment with a chemotherapy regimen using cyclosporin-A as a Pgp modulator selected for LRP overexpression despite a decrease or loss of Pgp expression (Table 4 ). This observation confirms that LRP may identify leukemic clones distinct from those harboring Pgp and is in agreement with results of in vitro selection studies. Myeloma cell lines selected for resistance to both doxorubicin and the Pgp modulator verapamil show LRP overexpression but lack Pgp (W.S. Dalton, unpublished data).
Our findings that LRP has independent prognostic relevance in AML indicates that this novel transport protein may contribute to chemotherapy resistance in this disease. These results require confirmation in a larger cohort of uniformly treated patients. Nevertheless, the relatively high prevalence of LRP overexpression observed in AML and its apparent selection by cyclosporin-A suggests that this drug-resistance phenotype may limit the effectiveness of Pgp modulators in clinical trials. The latter is under investigation in a Southwest Oncology Group trial in which participants are randomized to an anthracyclinecontaining induction regimen, with or without addition of cyclosporin-A. In a recent report from the Free University of Amsterdam,47 LRP overexpression conferred a lower response rate to cisplatin-based chemotherapy in patients with ovarian cancer, indicating that the prognostic value of LRP extends to other malignancies. Based on these findings and the results of the present study, development of strategies to overcome LRP-related MDR appears warranted. 
